How to Cite
Abstract
Recent advances in the development and administration of therapy for malignant diseases have been rewarded with prolonged survival rates. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxicity is directed against the peripheral nerve, resulting in cancer therapy-induced peripheral neuropathy. Chemotherapeutic agents used to treat hematologic and solid tumors target a variety of structures and functions in the peripheral nervous system, including the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures. Each agent exhibits a spectrum of effects unique to its mechanism of action, and recent studies in this field have yielded clearer ideas on how to mitigate injury. Combined with the call for a greater recognition of the devastating effects of cancer therapy-induced peripheral neuropathy on quality of life, basic and clinical researchers have begun to investigate therapy to prevent and treat neurologic damage. This review was made based on relevant information avaliable on international databases concerning cancer therapy-induced peripheral neuropathy and summarizes the evidence for diagnosis, pharmacologic and nonpharmacologic approaches to the management of this commonly unrecognized condition. In conclusion, the information avaliable in this moment establish the mechanisms of the disease and exposes the importance of the development of statistically stronger clinical trials that complement current data available in this moment. (MÉD.UIS. 2010;23(1):100-19)
Key words: Peripheral neuropathy. Neoplasm. Peripheral nervous system diseases/chemicall induced. Chemotherapy. Taxane. Vincristine. Cisplatin. Antineoplastic agents. Adverse effects.
References
2. Weiss RB. Toxicity of chemotherapy – The last decade. Sem Oncol. 2006;33(1):1.
3. Brennan MF. Randomized clinical trials in oncology commentary. Surg Oncol Clin N Am. 2002;11(1):1-2.
4. Plancarte SR, Mille-Loera J, Mayer-Rivera F. Manejo del dolor en cáncer. Cir Ciruj 2002;70:356-68.
5. Bennett GJ: Neuropathic pain: new insights, new interventions. Hosp Pract 1998;33:95-8.
6. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
7. Markman M. Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Pain Head Rep 2006;10:275-8.
8. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management and evaluation of chemotherapy induced peripheral neuropathy. Sem Oncol 2006;33(1);15-49.
9. Sommer C. Painful neuropathies. Curr Opinion Neurol 2003;16:623-8.
10. Dworkin R. An overview of neuropathic pain: Syndromes, symptons, signs, and several mechanisms. Clin J Pain 2002;18:343-9.
11. Morley-Forster P. Prevalence of neuropathic pain and the need for treatment. Pain Res Manag 2006;11(Suppl A):5A-10A.
12. Davis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 2004;21(2):137-42.
13. Anastasia P, Hay JW. Chemotherapy-induced neuropathy: results of an oncology nurse survey. Proc Am Soc Clin Oncol 2002;21:2618.
14. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-73.
15. Edwards M. The Functional Implications of Taxane-induced Neuropathy. California Breast Cancer Research Program 2004, grant number 10GB-0001.
16. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty Pm. Clinical and experimental findings in humans and animals with chemotherapy induced peripheral neuropathy. Minerva Anestesiol 2006;72:151-169.
17. Hilkens PHE, Verweij J, Vech ChJ, Stoter G, Van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel. Ann Oncol 1997;8:1-4.
18. Forman A. Peripheral neuropathy in cancer patients: clinical types, etiology and presentation. Oncology 1990;4:85-9.
19. Grothey A. Oxaliplatin safety profile: Neurotoxicity. Semin Oncol 2003;30(suppl 15):5-13.
20. Brienza S, Vignoud J, Itzakhi M. Oxaliplatin (L-OHP): Global safety in 682 patients. Proc Am Soc Clin Oncol 1999;14:209.
21. Raymond E, Faivre S, Woynarowski JM. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
22. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132(5):584-93.
23. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95.
24. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1(3):194-205.
25. Postma TJ, Bernard BA, Huijgens PC, Pssenkoppele GJ, Heimans JJ. Long term effects of vincristine on the peripheral nervous system. J Neuro-Oncol 1993;15:23-7.
26. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology 1983;90(1): 1-3.
27. Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediar Oncol1997;28(4):310-3.
28. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs2003;63(15):1549-63.
29. Masurovsky EB, Peterson ER, Crain SM. Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol. Neuroscience 1983;10:491-509.
30. Fazio R, Quattrini A, Bolognesi A. Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol 1999;98:651-3.
31. Screnci D, McKeage MJ. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 1999;77:105-10.
32. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002;349:9-17.
33. Weng HR, Aravindan N, Cata JP, Chen JH, Shaw AD, Dougherty PM. Spinal glial glutamate transporters downregulate in rats with taxol induced hyperalgesia. Neurosci Let 2005;386:18-22.
34. Cata JP, Weng HR, Chen JH, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006;138:329-38.
35. Di Maio M, Iaffaioli RV, de Placido de S. Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study. J Clin Oncol2005;23(suppl):458s.
36. National Cancer Institute. Cancer Therapy Evaluation Program, Common Toxicity Criteria. Version 2.0: April 30, 1999. URL: http://ctep.info.nih.govAcceso: Agosto 2009.
37. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading ofchemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61:1297-300.
38. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality-of-life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer2005 ;41:1135-9.
39. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13.
40. Postma TJ, Heimans JJ, Muller MJ. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;7:39-44.
41. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004;104:132–42.
42. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Iconomou A, Kalofonos HP, et al. Peripheral neuropathy induced by administration of cisplatin and paclitaxel-based